GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Fatty Liver Disease/Nutrition in MASLD: Frontline Gastroenterology | April 2026
42

Nutrition in MASLD: Frontline Gastroenterology | April 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated April 1, 2026

Introduction

Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading cause of chronic liver disease worldwide and closely parallels the epidemics of obesity and type 2 diabetes. Lifestyle modification remains the first-line, evidence-based treatment, but in real practice there is often a major gap between guideline advice and what patients are actually able to follow. This review focuses on nutrition as the central modifiable factor in MASLD care, while also recognizing the importance of physical activity, sleep, culture, affordability, and food access.

Problem Statement

The major challenge in MASLD is not only knowing that diet matters, but translating broad recommendations into realistic, culturally sensitive, affordable, and sustainable nutrition advice for individual patients in busy clinical practice.

Summary

This review makes a strong case that nutrition should be at the centre of MASLD management. The main dietary message is to reduce ultra-processed foods, sugar-sweetened beverages, commercially produced fructose, saturated fats, and excess calories, while encouraging whole foods, vegetables, fruits, legumes, wholegrains, nuts, seeds, olive or rapeseed oil, and oily fish. The Mediterranean diet remains the most evidence-supported pattern because it improves liver fat and cardiometabolic health, sometimes even without significant weight loss. However, the authors rightly stress that the best diet is the one a patient can actually follow long term, so dietary advice must be personalized and culturally adapted.

The review also explains the role of macronutrients and micronutrients. Fructose and saturated fat promote steatosis, while fibre, unsaturated fats, and adequate protein intake are protective. Micronutrients such as vitamin E, vitamin D, vitamin C, zinc, and polyphenols may influence liver health, although routine supplementation is not broadly recommended unless there is deficiency or a specific indication. Alcohol avoidance is emphasized, especially in more advanced disease.

A particularly valuable part of this paper is its practical approach. It recognizes food insecurity, cost, and social context as real barriers. It gives adaptable Mediterranean-style advice for South and Southeast Asian, African, and lower-income populations, and even provides simple clinic checklists and sample menus. The overall message is clear: MASLD nutrition care should move from generic advice to compassionate, individualized, practical counselling that patients can sustain.

Related Q&A

43

AI-Based Hepatic Fibre Phenotyping in MASLD: Hepatology | April 2026

Introduction Metabolically–dysfunction–associated steatotic liver disease (MASLD) is a complex and heterogeneous condition where fibrosis plays a central role in disease progression and hepatocellular carcinoma (HCC) risk. Traditional histological...

44

Lean MASLD: Gut | April 2026

Introduction Metabolic dysfunction–associated steatotic liver disease (MASLD) has traditionally been linked with obesity and metabolic syndrome. However, an emerging subset—lean MASLD—is increasingly recognised, particularly in Asian populations. Despite...

45

Combination Therapies for MASH: JOH, April 2026

Introduction Metabolically–dysfunction–associated steatohepatitis (MASH) is a complex, multisystem disease driven by obesity, insulin resistance, lipotoxicity, inflammation, and fibrosis. Traditional single-drug therapies have shown limited success because they target...

46

MASLD in Children and Adolescents: Journal of Hepatology | March 2026

Introduction Pediatric metabolic dysfunction-associated steatotic liver disease is increasingly recognized as one of the most important chronic liver diseases in children and adolescents, paralleling the global rise in...

47

Ketogenic Diets in MASLD: Journal of Hepatology | March 2026

Introduction Ketogenic diets, characterized by very low carbohydrate intake and increased fat consumption, have gained significant attention as a potential therapeutic strategy in metabolic dysfunction-associated steatotic liver disease....

48

GLP-1 RA in Gastroenterology: Digestive and Liver Disease | March 2026

Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now widely used for type 2 diabetes and obesity, two conditions frequently encountered in gastroenterology practice. Their effects extend far beyond...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer